According to a recent AHA Scientific Statement, despite ongoing limitations, recent advances in genomic sequencing ...
THETFORD MINES, QC, Dec. 22, 2025 /CNW/ – KDA Group Inc. (TSXV: KDA) (“KDA” or the “Corporation”), a leader in innovative ...
Vossman discusses the genomics landscape, as well as next-generation sequencing (or NGS), and the Model Project, a ...
Biomarker Therapy in 2025: More Lung Cancer Options, Competition in New Drug Classes, ctDNA Advances
This year, there was a surge of new lung cancer treatments, more options for patients with earlier-stage disease, and growing evidence on the utility of ctDNA testing.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback